Efficacy and Safety of Suvorexant (MK-4305) for Reducing Incidence of Delirium in Japanese Participants at High Risk of Delirium (MK-4305-085)

PHASE3CompletedINTERVENTIONAL
Enrollment

207

Participants

Timeline

Start Date

October 22, 2020

Primary Completion Date

December 23, 2022

Study Completion Date

December 23, 2022

Conditions
Delirium
Interventions
DRUG

Suvorexant

Suvorexant administered at a dose of 15 mg QD via oral tablet

DRUG

Placebo

Suvorexant-matching placebo administered QD via oral tablet

Trial Locations (50)

2360064

Yokohama City University Hospital ( Site 8515), Yokohama

7008558

Okayama University Hospital ( Site 8510), Okayama

272-8516

Kohnodai Hospital, National Center for Global Health and Medicine ( Site 8522), Ichikawa

Unknown

Iizuka Hospital ( Site 8540), Iizuka

Tokyo Medical and Dental University Hospital ( Site 8503), Tokyo

802-8555

Kokura Memorial Hospital ( Site 8537), Kitakyushu

371-0811

Maebashi Red Cross Hospital ( Site 8548), Maebashi

721-8511

Fukuyama City Hospital ( Site 8528), Fukuyama

060-0004

Tonan Hospital ( Site 8512), Sapporo

660-8511

Kansai Rosai Hospital ( Site 8550), Amagasaki

920-0293

Kanazawa Medical University Hospital ( Site 8514), Kahoku-gun

920-8650

National Hospital Organization Kanazawa Medical Center ( Site 8554), Kanazawa

761-0793

Kagawa University Hospital ( Site 8519), Kita-gun

760-0017

TAKAMATSU Red Cross Hospital ( Site 8547), Takamatsu

211-8533

Nippon Medical School Musashi Kosugi Hospital ( Site 8502), Kawasaki

224-8503

Showa University Northern Yokohama Hospital ( Site 8534), Yokohama

232-0024

Yokohama City University Medical Center ( Site 8516), Yokohama

234-8503

Saiseikai Yokohamashi Nanbu Hospital ( Site 8541), Yokohama

245-8575

National Hospital Organization Yokohama Medical Center ( Site 8531), Yokohama

625-8502

National Hospital Organization Maizuru Medical Center ( Site 8535), Maizuru-shi

390-8510

Aizawa Hospital ( Site 8542), Matsumoto

570-8540

Matsushita Memorial Hospital ( Site 8556), Moriguchi

565-0871

Osaka University Hospital ( Site 8524), Suita

560-8565

Toyonaka Municipal Hospital ( Site 8521), Toyonaka

693-8555

Shimane Prefectural Central Hospital ( Site 8530), Izumo

322-8550

Kamitsuga General Hospital ( Site 8546), Kanuma

327-8511

SANO KOSEI GENERAL HOSPITAL ( Site 8551), Sano

329-0498

Jichi Medical University Hospital ( Site 8525), Shimotsuke

755-8505

Yamaguchi University Hospital ( Site 8517), Ube

810-8563

National Hospital Organization Kyushu Medical Center ( Site 8532), Fukuoka

500-8513

Gifu Municipal Hospital ( Site 8555), Gifu

730-8518

Hiroshima City Hiroshima Citizens Hospital ( Site 8505), Hiroshima

860-0008

National Hospital Organization Kumamoto Medical Center ( Site 8511), Kumamoto

602-8026

Japanese Red Cross Kyoto Daini Hospital ( Site 8533), Kyoto

615-8256

Kyoto Katsura Hospital ( Site 8539), Kyoto

880-8510

Miyazaki Prefectural Miyazaki Hospital ( Site 8543), Miyazaki

950-1197

Niigata City General Hospital ( Site 8544), Niigata

700-8511

Okayama Saiseikai General Hospital ( Site 8549), Okayama

534-0021

Osaka City General Hospital ( Site 8518), Osaka

540-0006

National Hospital Organization Osaka National Hospital ( Site 8536), Osaka

543-8555

Japanese Red Cross Osaka Hospital ( Site 8523), Osaka

550-0006

Nippon Life Hospital ( Site 8552), Osaka

553-0003

Japan Community Health care Organization Osaka Hospital ( Site 8545), Osaka

558-8558

Osaka General Medical Center ( Site 8538), Osaka

840-8571

Saga-Ken Medical Centre Koseikan ( Site 8526), Saga

770-8539

Tokushima Prefectural Central Hospital ( Site 8509), Tokushima

104-0045

National Cancer Center Hospital ( Site 8520), Tokyo

152-8902

National Hospital Organization Tokyo Medical Center ( Site 8529), Tokyo

162-8666

Tokyo Women's Medical University Hospital ( Site 8527), Tokyo

177-8521

Juntendo University Nerima Hospital ( Site 8501), Tokyo

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT04571944 - Efficacy and Safety of Suvorexant (MK-4305) for Reducing Incidence of Delirium in Japanese Participants at High Risk of Delirium (MK-4305-085) | Biotech Hunter | Biotech Hunter